NASDAQ:IPHA • US45781K2042
Overall IPHA gets a fundamental rating of 2 out of 10. We evaluated IPHA against 520 industry peers in the Biotechnology industry. Both the profitability and financial health of IPHA have multiple concerns. IPHA does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.55% | ||
| ROE | -895.24% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.52% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.52 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.5 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.21 | ||
| Quick Ratio | 2.21 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:IPHA (3/2/2026, 8:00:02 PM)
1.65
-0.07 (-3.79%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 22.03 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 25.69 | ||
| P/tB | 25.69 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.55% | ||
| ROE | -895.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.52% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.52 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.84% | ||
| Cap/Sales | 2.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.21 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | -6.5 |
ChartMill assigns a fundamental rating of 2 / 10 to IPHA.
ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.
INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.
The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 2 / 10.